DRAFT — content pending medical review. Do not share.

Peptide Library / Weight & Metabolic

Cagrilintide

Also known as: The amylin half of "CagriSema"

The next weight-loss mechanism — an amylin analog that creates satiety through a completely different pathway than GLP-1, designed to pair with semaglutide.

Typical research dose0.25–0.5 mg/week to start; trial range up to 4.5 mg/week
Frequency1× weekly
RouteSubcutaneous injection
Cycle lengthOngoing with titration; not a short cycle

Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.

What it is

Cagrilintide is a long-acting analog of amylin — the hormone your pancreas releases alongside insulin that tells your brain "meal registered, stop eating." It's Novo Nordisk's designed partner for semaglutide: the combination (CagriSema) is in late-stage trials on the thesis that hitting satiety through two different pathways beats pushing one pathway harder.

What the research looks at

How protocols are commonly structured

Trial design is the template: start 0.25–0.5 mg once weekly, titrate every 4 weeks as tolerated (trial range ran to 4.5 mg). In combination protocols it's dosed the same day as the GLP-1 partner. The class rules carry over: slow ladder, protein, resistance training, track more than the scale — and the standing medullary-thyroid-history exclusion that applies across this whole category.

Reconstitution & storage

Lyophilized powder; bacteriostatic-water reconstitution (calculator), weekly mg dosing, refrigerate after mixing.

Research protocols, not a prescription — talk to a physician before touching anything.